December 2, 2022
Ferring Pharmaceuticals has granted the Japan marketing rights of its ulcerative colitis drug candidate FE999315, currently pending regulatory approval, to Mochida Pharmaceutical, the two companies said on December 1. Under this licensing deal, Mochida will be responsible for the distribution...read more